The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance for clinical trials in oncology trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.
 
Matthew H. G. Katz
Consulting or Advisory Role - Abbvie; Alcresta Therapeutics; McKesson
 
Fang-Shu Ou
No Relationships to Disclose
 
Joseph Herman
Consulting or Advisory Role - Abbvie; BTG
Research Funding - Oncosil (Inst)
Patents, Royalties, Other Intellectual Property - Elekta (Inst)
Travel, Accommodations, Expenses - Abbvie; BTG; Hitachi Chemical
 
Syed A. Ahmad
Consulting or Advisory Role - Abbvie
Speakers' Bureau - Abbvie
 
Brian M. Wolpin
Consulting or Advisory Role - Genentech
 
Robert de Wilton Marsh
No Relationships to Disclose
 
Qian Shi
No Relationships to Disclose
 
Joleen Marie Hubbard
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Genentech/Roche (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); Genentech (Inst); Merck (Inst); Senhwa Biosciences (Inst)
 
Jeffrey A. Meyerhardt
Research Funding - Biothera (Inst)
 
Michael Chuong
Honoraria - Quantia MD
Consulting or Advisory Role - Sirtex Medical
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Agios (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blueprint Medicines (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); Delcath Systems (I); Eisai (I); Gilead Sciences; Halozyme (I); IntegraGen (I); Ipsen (I); Janssen; MedImmune; Merck (I); Merrimack; New B Innovation (I); Newlink Genetics; Onxeo (I); Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); VAXIMM; Vicus Therapeutics; Westhaven (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst)